Jung E. Choi
Ms. Choi currently serves as chief business and strategy officer of Global Blood Therapeutics, Inc., a biopharmaceutical company. In her role she is responsible for spearheading the company’s business development activities and corporate strategy, including identifying and executing strategic transactions to drive corporate value. She also oversees patient advocacy, government affairs and policy, and program team leadership for a clinical program. During her career, Ms. Choi has led or managed over 50 transactions exceeding $13 billion in value. Prior to Global Blood Therapeutics, Ms. Choi served as senior vice president, corporate development for InterMune, Inc., a biotechnology company (acquired by Roche Holding AG). Before that, Ms. Choi served as senior vice president, corporate development and consultant for Chimerix, Inc. Earlier in her career, Ms. Choi held various management positions at Gilead Sciences, Inc. including leadership of business development, licensing, and mergers and acquisition activities. During her tenure at Gilead, Ms. Choi built and oversaw the corporate development group, and led the U.S. commercial launch of Hepsera® for the treatment of the hepatitis B virus. She also has venture capital and strategy experience, having served as a vice president at Bay City Capital and an engagement manager at McKinsey & Company. Ms. Choi is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Ms. Choi received her B.A. in human biology and an M.B.A. from Stanford University.